Based on the known effects of ARBs to reduce TGF-β release, we hypothesized that patients undergoing SBRT for early stage NSCLC have increased survival and decreased recurrence compared to patients not on ARBs. Here, TGFB1 is linked to non-small cell lung carcinoma.